Login to Your Account

Financings Roundup

Newlink Adds $42.5M in Public Offering for Immunotherapies

By Catherine Shaffer
Staff Writer

Thursday, January 31, 2013
NewLink Genetics Corp.'s HyperAcute technology will get a boost from a public offering of 4 million shares of common stock in the company priced at $11.40 per share, or net proceeds of $42.5 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription